However, treatment with an IL-36R-blocking antibody of TNF-transgenic mice, another experimental model of RA, resulted in no changes in symptoms or clinical onset, suggesting that the severity of experimental arthritis is independent of IL-36R signaling [38, 39]. The gene discussed is IL1RL2; the disease is arthritic joint disease.